Direct-acting antivirals for children and adolescents with chronic hepatitis C

The Lancet Child and Adolescent Health

Volumn 2, Issue 4, 2018, Pages 298-304

  Indolfi, Giuseppe ^a   Serranti, Daniele ^a   Resti, Massimo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; GLECAPREVIR PLUS PIBRENTASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR;

CHRONIC HEPATITIS C; DRUG EFFECT; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG USE; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HUMAN; QUALITY OF LIFE; REVIEW; ADOLESCENT; CHILD; DRUG COMBINATION;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; DRUG COMBINATIONS; HEPATITIS C, CHRONIC; HUMANS;

EID: 85043577286     PISSN: None     EISSN: 23524642     Source Type: Journal    
DOI: 10.1016/S2352-4642(18)30037-3     Document Type: Review

References (40)

1. Thorne, C, Indolfi, G, Turkova, A, Giaquinto, C, Nastouli, E, Treating hepatitis C virus in children: time for a new paradigm. J Virus Erad 1 (2015), 203–205.
2. Balistreri, WF, Murray, KF, Rosenthal, P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology 66 (2017), 371–378.
3. Wirth, S, Rosenthal, P, Gonzalez-Peralta, RP, et al. Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 66 (2017), 1102–1110.
4. Hashmi, MA, Cheema, HA, Effectiveness and safety of sofosbuvir in treatment-naive children with hepatitis C infection. J Coll Physicians Surg Pak 27 (2017), 423–426.
5. Younossi, ZM, Stepanova, M, Balistreri, W, et al. Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with sofosbuvir and ledipasvir. J Pediatr Gastroenterol Nutr 66 (2018), 112–116.
6. Kirby, B, German, P, Kanwar, B, et al. Pharmacokinetics of once daily sofosbuvir or ledipasvir/sofosbuvir in HCV-infected adolescents. Hepatology, 62(S1), 2015 abstr 1707.
7. Garrison K, Mathias A, Kersey K, et al. Pharmacokinetics of once daily sofosbuvir or ledipasvir/sofosbuvir in HCV-infected pediatrics aged 6 to <12 years old. The Liver Meeting; Boston; Nov 11–15, 2016. Abstr 878.
8. Schwarz K, Murray K, Rosenthal P, et al. High rates of SVR12 in adolescents treated with the combination of ledipasvir/sofosbuvir. The International Liver Congress; Barcelona; April 13–17, 2016. Abstr GS17.
9. Balistreri, W, Rosenthal, P, Bansal, S, et al. Ledipasvir/sofosbuvir for 12 weeks is safe and effective in adolescents with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 63:S2 (2016), S140–S141 Abstr 420.
10. Murray, KF, Balistreri, W, Bansal, S, et al. Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks is safe and effective in children 6–11 years old with chronic hepatitis C infection. J Hepatol, 66, 2017, PS101.
11. Schwarz, KB, Rosenthal, P, Gonzalez-Peralta, RP, et al. Sofosbuvir + ribavirin for 12 or 24 weeks is safe and effective in adolescents with genotype 2 or genotype 3 chronic hepatitis C infection. Hepatology, 64(S1), 2016 abstr 706.
12. Younossi, ZM, Stepanova, M, Balistreri, W, et al. High efficacy and significant improvement of quality of life (QoL) in adolescent patients with hepatitis C genotype 1 (GT1) treated with sofosbuvir (SOF) and ledipasvir (LDV). Hepatology, 64(S1), 2016 abstr 709.
13. Leung DH, Yao B, Gonzalez-Peralta R, et al. ZIRCON: pharmacokinetics, safety, and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in adolescents with genotype 1 or 4 hepatitis C virus infection. The International Liver Congress; Amsterdam; April 19–23, 2017. Abstr THU-251.
14. Leung D, Yao B, Viani R, et al. Pharmacokinetics, safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C genotype 1 or 4 virus infected adolescents: the Zircon study. 2017 Annual Meeting of the European Society of Pediatric Infectious Disease; Madrid; May 23–27, 2017. Abstr 1125.
15. El-Sayed M, Hassany M, Asem N. A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in Egyptian adolescents with chronic hepatitis C virus infection. The International Liver Congress; Amsterdam; April 19–23, 2017. Abstr THU-412.
16. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org (accessed Feb 10, 2018).
17. Indolfi, G, Hierro, L, Dezsofi, A, et al. Treatment of chronic hepatitis C virus infection in children. A position paper by the Hepatology Committee of ESPGHAN. J Pediatr Gastroenterol Nutr, 2017 published online Dec 28. DOI: 10.1097/MPG.0000000000001872.
18. Wirth, S, Ribes-Koninckx, C, Calzado, MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 52 (2010), 501–507.
19. Sokal, EM, Bourgois, A, Stéphenne, X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 52 (2010), 827–831.
20. Indolfi, G, Nebbia, G, Cananzi, M, et al. Kinetic of virologic response to pegylated interferon and ribavirin in children with chronic hepatitis C predicts the effect of treatment. Pediatr Infect Dis J 35 (2016), 1300–1303.
21. Granot, E, Sokal, EM, Hepatitis C virus in children: deferring treatment in expectation of direct-acting antiviral agents. Isr Med Assoc J 17 (2015), 707–711.
22. Lee, CK, Jonas, MM, Hepatitis C: issues in children. Gastroenterol Clin North Am 44 (2015), 901–909.
23. Indolfi, G, Thorne, C, El Sayed, MH, Giaquinto, C, Gonzalez-Peralta, RP, The challenge of treating children with hepatitis C virus infection. J Pediatr Gastroenterol Nutr 64 (2017), 851–854.
24. Bortolotti, F, Verucchi, G, Cammà C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 134 (2008), 1900–1907.
25. Network, EPHCV, Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 41 (2005), 45–51.
26. Guido, M, Bortolotti, F, Leandro, G, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time?. Am J Gastroenterol 98 (2003), 660–663.
27. Goodman, ZD, Makhlouf, HR, Liu, L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 47 (2008), 836–843.
28. Minola, E, Prati, D, Suter, F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 99 (2002), 4588–4591.
29. Badizadegan, K, Jonas, MM, Ott, MJ, Nelson, SP, Perez-Atayde, AR, Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 28 (1998), 1416–1423.
30. Harris, HE, Mieli-Vergani, G, Kelly, D, et al. A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease. J Pediatr Gastroenterol Nutr 45 (2007), 335–341.
31. Schwarz, KB, Gonzalez-Peralta, RP, Murray, KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 140 (2011), 450–458.
32. Nydegger, A, Srivastava, A, Wake, M, Smith, AL, Hardikar, W, Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol 23 (2008), 226–230.
33. Rodrigue, JR, Balistreri, W, Haber, B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 48 (2009), 341–347.
34. EASL. EASL Recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
35. WHO. Global Hepatitis Report 2017. 2017, World Health Organization, Geneva.
36. El-Sayed, M, Razavi, H, Global estimate of HCV infection in the pediatric and adolescent population. J Hepatol 62 (2015), 831–832.
37. WHO. Global health sector strategy on viral hepatitis 2016–2021. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/, 2016 (accessed Feb 10, 2018).
38. Omata, M, Kanda, T, Wei, L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 10 (2016), 702–726.
39. WHO. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/, 2016 (accessed Feb 10, 2018).
40. Hoofnagle, JH, Sherker, AH, Therapy for hepatitis C—the costs of success. N Engl J Med 370 (2014), 1552–1553.